HER2+ Breast Cancer | Specialty

Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer

July 12th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.

TCH+P Still Standard Choice for Patients With HER2+ Breast Cancer

July 10th 2016

Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.

Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

July 9th 2016

Dr. Esteva on Trastuzumab Biosimilar in Patients With HER2+ Breast Cancer

July 7th 2016

Francisco J. Esteva, MD, PhD, medical oncology, New York Langone Medical Center, discusses a phase III study of the biosimilar version of trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.

Phase III Nelipepimut-S Study in Breast Cancer Halted After Futility Review

June 30th 2016

A phase III trial investigating the first-in-class immunotherapy vaccine nelipepimut-S (NeuVax) for the prevention of recurrence in early-stage breast cancer has been stopped due to futility.

Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

June 29th 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology) and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses how surgical oncologists should approach the treatment of a patient with HER2-positive breast cancer.

EMA Approval Sought for Neratinib in HER2+ Breast Cancer

June 28th 2016

A marketing authorization application has been submitted to the European Medicines Agency for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Final Thoughts on Advanced Breast Cancer

June 23rd 2016

Practice-Changing Results from the MINDACT Trial

June 23rd 2016

AC versus TaxAC in High-Risk HER2-Negative MBC

June 23rd 2016

Adjuvant Therapy for Breast Cancer

June 23rd 2016

Immunotherapy for TNBC

June 23rd 2016

Is There a Role for TNBC Subtyping?

June 23rd 2016

Biosimilar Trastuzumab in HER2-Positive Breast Cancer

June 23rd 2016

Neratinib and HER2 Activating Mutations in Breast Cancer

June 23rd 2016

Patient Selection for Neratinib in Metastatic Breast Cancer

June 23rd 2016

The Emerging Role of Neratinib in HER2+ MBC

June 23rd 2016

PHEREXA Trial in HER2+ Disease

June 23rd 2016

Adjuvant TDM-1 and the KRISTINE Trial

June 23rd 2016

What is New for HER2 MBC?

June 23rd 2016